Foot Anstey advises Stanley Capital Partners on its investment into a majority stake in French pharmaceutical group Laboratoire XO (Lab XO)

The Private Equity team at national law firm, Foot Anstey LLP has supported and advised Stanley Capital Partners (SCP) on its investment in a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US lending giant Ares Management.

Headquartered in Saint Cloud, France and founded in 2015, Lab XO specialises in mature market authorisations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care, and women’s health. With a turnover of €60m, 26 brands, and a distribution network of more than 45 countries (US, Europe, the Maghreb, and the Francophone world), the Lab XO team has demonstrated strong capabilities to integrate mature brands from big pharma and to generate organic growth through life cycle management.

SCP's strategic investment in Lab XO will support Lab XO's next phase of growth.

Foot Anstey led on the acquisition of the Lab XO business and the team included Matt Stoate (Partner) and Emma Clayton (Senior Associate). The team advised on the legalities of the acquisition and worked collaboratively with Willkie Farr & Gallagher (debt, equity), Loyens Loeff and d'Ornano et Associes (due diligence) to ensure a successful outcome.

Matt Stoate, Head of Corporate and Private Equity at Foot Anstey, said: “SCP has a proven track record of investing in businesses and bolstering growth and we enjoyed working collaboratively across the legal advisory team to ensure a smooth and successful transaction. Our unique positioning in the market means that our Private Equity team is well-placed to advise on matters such as these. We look forward to seeing SCP and Lab XO's steps towards further global growth."

Editors contacts

James Grice – [email protected] or +44 117 9154982         

Matt Samuel – [email protected] or +44 117 9154998